These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 16001174

  • 1. Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors.
    Rodriguez-Galindo C, Crews KR, Stewart CF, Furman W, Panetta JC, Daw NC, Cain A, Tan M, Houghton PH, Santana VM.
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):15-24. PubMed ID: 16001174
    [Abstract] [Full Text] [Related]

  • 2. Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors.
    Levy AS, Meyers PA, Wexler LH, Jakacki R, Angiolillo A, Ringuette SN, Cohen MB, Gorlick R.
    Cancer; 2009 Jan 01; 115(1):207-16. PubMed ID: 19090012
    [Abstract] [Full Text] [Related]

  • 3. Phase I study of docetaxel and topotecan in patients with solid tumors.
    Tkaczuk KH, Zamboni WC, Tait NS, Meisenberg BR, Doyle LA, Edelman MJ, Hausner PF, Egorin MJ, Van Echo DA.
    Cancer Chemother Pharmacol; 2000 Jan 01; 46(6):442-8. PubMed ID: 11138457
    [Abstract] [Full Text] [Related]

  • 4. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Fields S, Von Hoff DD, Verweij J.
    Clin Cancer Res; 1998 May 01; 4(5):1153-8. PubMed ID: 9607572
    [Abstract] [Full Text] [Related]

  • 5. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children.
    Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, Bowman LC, Ma MK, Hoffer FA, Meyer WH, Pappo AS, Walter AW, Houghton PJ.
    J Clin Oncol; 1999 Jun 01; 17(6):1815-24. PubMed ID: 10561220
    [Abstract] [Full Text] [Related]

  • 6. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study.
    Tubergen DG, Stewart CF, Pratt CB, Zamboni WC, Winick N, Santana VM, Dryer ZA, Kurtzberg J, Bell B, Grier H, Vietti TJ.
    J Pediatr Hematol Oncol; 1996 Nov 01; 18(4):352-61. PubMed ID: 8888741
    [Abstract] [Full Text] [Related]

  • 7. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
    Pentheroudakis G, Briasoulis E, Karavassilis V, Mauri D, Tzamakou E, Rammou D, Pavlidis N.
    Chemotherapy; 2005 May 01; 51(2-3):154-61. PubMed ID: 15886476
    [Abstract] [Full Text] [Related]

  • 8. Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors.
    Souid AK, Dubowy RL, Blaney SM, Hershon L, Sullivan J, McLeod WD, Bernstein ML.
    Clin Cancer Res; 2003 Feb 01; 9(2):703-10. PubMed ID: 12576438
    [Abstract] [Full Text] [Related]

  • 9. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.
    Wagner LM, Crews KR, Iacono LC, Houghton PJ, Fuller CE, McCarville MB, Goldsby RE, Albritton K, Stewart CF, Santana VM.
    Clin Cancer Res; 2004 Feb 01; 10(3):840-8. PubMed ID: 14871959
    [Abstract] [Full Text] [Related]

  • 10. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
    Rowinsky EK, Grochow LB, Sartorius SE, Bowling MK, Kaufmann SH, Peereboom D, Donehower RC.
    J Clin Oncol; 1996 Apr 01; 14(4):1224-35. PubMed ID: 8648378
    [Abstract] [Full Text] [Related]

  • 11. Phase I clinical trial of weekly combined topotecan and irinotecan.
    Lokich J.
    Am J Clin Oncol; 2001 Aug 01; 24(4):336-40. PubMed ID: 11474256
    [Abstract] [Full Text] [Related]

  • 12. Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors.
    McNall-Knapp RY, Williams CN, Reeves EN, Heideman RL, Meyer WH.
    Pediatr Blood Cancer; 2010 Jul 01; 54(7):909-15. PubMed ID: 20405511
    [Abstract] [Full Text] [Related]

  • 13. Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: a phase I study.
    Briasoulis E, Pentheroudakis G, Timotheadou H, Rammou D, Pavlidis N, Fountzilas G.
    Anticancer Drugs; 2004 Sep 01; 15(8):747-52. PubMed ID: 15494635
    [Abstract] [Full Text] [Related]

  • 14. Camptothecin analogues: studies from the Johns Hopkins Oncology Center.
    Slichenmyer WJ, Rowinsky EK, Grochow LB, Kaufmann SH, Donehower RC.
    Cancer Chemother Pharmacol; 1994 Sep 01; 34 Suppl():S53-7. PubMed ID: 7520844
    [Abstract] [Full Text] [Related]

  • 15. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.
    Drengler RL, Kuhn JG, Schaaf LJ, Rodriguez GI, Villalona-Calero MA, Hammond LA, Stephenson JA, Hodges S, Kraynak MA, Staton BA, Elfring GL, Locker PK, Miller LL, Von Hoff DD, Rothenberg ML.
    J Clin Oncol; 1999 Feb 01; 17(2):685-96. PubMed ID: 10080615
    [Abstract] [Full Text] [Related]

  • 16. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
    Thompson J, George EO, Poquette CA, Cheshire PJ, Richmond LB, de Graaf SS, Ma M, Stewart CF, Houghton PJ.
    Clin Cancer Res; 1999 Nov 01; 5(11):3617-31. PubMed ID: 10589779
    [Abstract] [Full Text] [Related]

  • 17. Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942.
    Wells RJ, Reid JM, Ames MM, Mares WL, Krailo MD, Seibel NL, Mosher R, Reaman GH, Wiersma SR.
    J Pediatr Hematol Oncol; 2002 Feb 01; 24(2):89-93. PubMed ID: 11990712
    [Abstract] [Full Text] [Related]

  • 18. Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
    Boss DS, Siegel-Lakhai WS, van Egmond-Schoemaker NE, Pluim D, Rosing H, Ten Bokkel Huinink WW, Beijnen JH, Schellens JH.
    Clin Cancer Res; 2009 Jul 01; 15(13):4475-83. PubMed ID: 19531625
    [Abstract] [Full Text] [Related]

  • 19. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
    Blaney SM, Needle MN, Gillespie A, Sato JK, Reaman GH, Berg SL, Adamson PC, Krailo MD, Bleyer WA, Poplack DG, Balis FM.
    Clin Cancer Res; 1998 Feb 01; 4(2):357-60. PubMed ID: 9516923
    [Abstract] [Full Text] [Related]

  • 20. Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.
    Saltz LB, Spriggs D, Schaaf LJ, Schwartz GK, Ilson D, Kemeny N, Kanowitz J, Steger C, Eng M, Albanese P, Semple D, Hanover CK, Elfring GL, Miller LL, Kelsen D.
    J Clin Oncol; 1998 Dec 01; 16(12):3858-65. PubMed ID: 9850031
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.